Health score, price, valuation, risk signals, and key metrics at a glance.
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (20/25); weakest: Balance Sheet & Red Flags (5/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently above its 4-quarter median.
Currently near its 19-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
Currently above its 14-quarter median.
D/E ratio is 14.6 — heavily leveraged and vulnerable to rising rates or cash flow dips.
4 of the last 8 quarters had negative FCF — inconsistent cash generation raises sustainability concerns.
Shares outstanding increased 36.4% — significant dilution, likely from stock compensation or capital raises.
